<SEC-DOCUMENT>0001157523-11-004615.txt : 20110803
<SEC-HEADER>0001157523-11-004615.hdr.sgml : 20110803
<ACCEPTANCE-DATETIME>20110803073059
ACCESSION NUMBER:		0001157523-11-004615
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110803
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110803
DATE AS OF CHANGE:		20110803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		111005295

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6816583.htm
<DESCRIPTION>CELLDEX THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font><font style="font-size: 10pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><font style="font-size: 10pt"><br style="font-size: 10pt"></font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman"><b>FORM
      8-K</b></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br>CURRENT
      REPORT<br><br><font style="font-size: 10pt; font-family: Times New Roman">PURSUANT
      TO SECTION 13 OR 15(d) OF</font><br><font style="font-size: 10pt; font-family: Times New Roman">THE
      SECURITIES EXCHANGE ACT OF 1934</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): &#160;</font><font style="font-size: 10pt; font-family: Times New Roman"><b>August
      3, 2011</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>CELLDEX
      THERAPEUTICS, INC.</b></font><br><i><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></i>
    </p>
    <p style="text-align: center">
      <br>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 33%">

        </td>
        <td valign="top" style="text-align: center; width: 34%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>0-15006</b><br>Commission File Number
          </p>
        </td>
        <td style="width: 33%">

        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; width: 33%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Delaware</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; width: 34%; white-space: nowrap; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; width: 33%; white-space: nowrap; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>13-3191702</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; width: 33%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(State or other jurisdiction</i>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>of incorporation)</i>
          </p>
        </td>
        <td valign="top" style="text-align: center; width: 34%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: center; width: 33%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(I.R.S. Employer</i>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>Identification No.)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; width: 25%; padding-left: 0.0px">
          &#160;
        </td>
        <td valign="bottom" style="text-align: center; width: 50%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>119 Fourth Avenue<br>Needham, Massachusetts 02494-2725</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; width: 25%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i><font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices) (Zip Code)</font></i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>(781)
      433-0771</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font><i><font style="font-size: 10pt; font-family: Times New Roman">(Registrant&#8217;s
      telephone number, including area code)</font></i><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman"></font>
    </p>
    <p style="text-align: center">

    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
      CFR 240.14a-12)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</font>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="white-space: nowrap">
      Item 2.02.&#160;&#160;Results of Operations and Financial Condition.
    </p>
    <p>
      On August 3, 2011, Celldex Therapeutics, Inc. issued a press release
      announcing its financial results for the second quarter of 2011.&#160;&#160;The
      full text of the press release is furnished as Exhibit 99.1 hereto and
      is incorporated by reference herein.
    </p>
    <p>
      The information in this Item 2.02 of this Current Report on Form 8-K and
      Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of
      Section 18 of the Securities Exchange Act of 1934, as amended (the
      &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that
      Section, nor shall such information be deemed incorporated by reference
      in any filing under the Securities Act of 1933, as amended (the
      &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set
      forth by specific reference in such a filing.
    </p>
    <p style="white-space: nowrap">
      Item 9.01.&#160;&#160;Financial Statements and Exhibits.
    </p>
    <p>
      (d) Exhibits
    </p>
    <p>
      99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release of Celldex Therapeutics, Inc., dated August 3,
      2011.
    </p>
    <p style="text-align: center">
      [Remainder of page left blank intentionally]
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">SIGNATURE</font><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, as
      amended, the registrant has duly caused this report to be filed on its
      behalf by the undersigned hereunto duly authorized.
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Celldex Therapeutics, Inc.
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td valign="top" style="text-align: left; width: 4%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 4%">
          &#160;
        </td>
        <td style="width: 36%">

        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 36%">

        </td>
        <td style="width: 11%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; width: 5%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; width: 25%; padding-left: 0.0px">
          August 3, 2011
        </td>
        <td style="width: 15%">

        </td>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; width: 4%; padding-left: 0.0px">
          By:
        </td>
        <td style="border-bottom: solid black 1.0pt; width: 4%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; width: 36%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Avery W. Catlin
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="text-align: left; width: 36%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Avery W. Catlin
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="text-align: left; width: 36%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Senior Vice President and
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="text-align: left; width: 36%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
    </table>
    </div>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      Exhibit Index<br>
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table style="margin-left:auto;margin-right:auto; margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-right: 0.0px; width: 5%; white-space: nowrap; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 5%; padding-left: 0.0px">
          &#160;
        </td>
        <td valign="top" style="text-align: left; width: 90%; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release of Celldex Therapeutics, Inc., dated August 3, 2011.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: left">

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6816583ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Celldex
      Reports Second Quarter 2011 Financial Results and Announces Finalization
      of Rindopepimut Pivotal Program Design</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>-
      Management to Host Conference Call Today at 8:30 AM Eastern Time -</b></font>
    </p>
    <p>
      NEEDHAM, Mass.--(BUSINESS WIRE)--August 3, 2011--Celldex Therapeutics,
      Inc. (NASDAQ: CLDX) today reported financial results for the second
      quarter ended June 30, 2011. Celldex reported a net loss of $10.2
      million, or $0.27 per share, for the second quarter of 2011 compared to
      a net loss of $9.5 million, or $0.30 per share, for the second quarter
      of 2010. For the six months ended June 30, 2011, Celldex reported a net
      loss of $20.3 million, or $0.58 per share, compared to a net loss of
      $16.1 million, or $0.51 per share, for the six months ended June 30,
      2010.
    </p>
    <p>
      At June 30, 2011, Celldex reported cash, cash equivalents and marketable
      securities of $71.2 million, an increase of $26.9 million from March 30,
      2011. The increase is due primarily to completion of an underwritten
      public offering in May, which resulted in net proceeds to Celldex of
      $33.7 million. The increase was partially offset by operational expenses
      during the quarter. Celldex believes that interest income on invested
      funds and current cash, cash equivalents and marketable securities as of
      June 30, 2011 are sufficient to meet estimated working capital
      requirements and fund planned operations into 2013.
    </p>
    <p>
      &#8220;Celldex achieved critical milestones across multiple corporate
      objectives,&#8221; said Anthony S. Marucci, President and Chief Executive
      Officer of Celldex. &#8220;Most importantly, after consultation with both US
      and EU regulatory authorities, we have finalized the protocol for the
      Phase 3 study of rindopepimut in glioblastoma, which will be called ACT
      IV, and expect to begin enrollment by year-end 2011. In addition, we
      also secured the financial means to support the initiation of ACT IV
      while maintaining the forward momentum of our other pipeline programs,
      netting a total of $33.7 million in an over-subscribed public offering.
      The significant progress made in the first half of 2011 will support a
      number of important events over the next 18 months.&#8221;
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Second quarter and recent highlights:</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Finalized the protocol for the ACT IV Phase 3 randomized,
        KLH-controlled, double-blind study of rindopepimut. KLH is a
        biologically active compound that is being utilized to mimic the overt
        signs of injection site reaction associated with rindopepimut. The
        primary endpoint of the study will be overall survival. The study is
        expected to enroll up to 374 patients with newly-diagnosed,
        resected,&#160;EGFRvIII expressing glioblastoma multiforme (GBM) at over
        150 clinical sites internationally. Enrollment is expected to begin in
        the second half of 2011.
      </li>
      <li style="margin-bottom: 10.0px">
        Continued brisk enrollment of the 120 patient, randomized Phase 2b
        study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing
        advanced, refractory breast cancer, including triple negative disease.
        This study is on track to fully accrue by year-end 2011.
      </li>
      <li style="margin-bottom: 10.0px">
        Completed an underwritten public offering in May of 11.5 million
        shares of common stock, which netted proceeds to Celldex of
        approximately $33.7 million, after deducting underwriting discounts,
        commissions and other estimated offering expenses payable by Celldex.
        The over-allotment was fully exercised.
      </li>
      <li style="margin-bottom: 10.0px">
        Hired Ronald A. Pepin, Ph.D., as Senior Vice President and Chief
        Business Officer, who formerly served as Vice President at Shire and
        previous as Senior Vice President, Business Development at Medarex,
        where he completed more than 40 major transactions.
      </li>
    </ul>
    <p>
      Based on Celldex&#8217;s ongoing commitment to prioritize the allocation of
      resources and to focus on its lead programs, the Company has determined
      that the best path forward for CDX-1307 is to make the candidate
      available for collaborative development. As such, Celldex has
      discontinued the Company-sponsored Phase 2 study of CDX-1307 in newly
      diagnosed muscle-invasive bladder cancer.
    </p>
    <p>
      <b>Upcoming events:</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        The Company expects to present final median overall survival data from
        the rindopepimut ACT III study at the Annual Meeting of the Society
        for Neuro-Oncology to be held November 17-20, 2011 in Orange County,
        CA.
      </li>
      <li style="margin-bottom: 10.0px">
        Celldex expects to initiate four new clinical trials by year-end 2011:

        <ul>
          <li style="margin-bottom: 10.0px">
            Phase 3 randomized, KLH-controlled, double-blind study of
            rindopepimut in patients with newly-diagnosed, resected GBM that
            express EGFRvIII. The ACT IV study is expected to enroll up to 374
            patients at over 150 clinical sites internationally.
          </li>
          <li style="margin-bottom: 10.0px">
            Phase 2 randomized study of rindopepimut alone or in combination
            with Avastin<sup>&#174;</sup> in recurrent or refractory GBM
            patients.
          </li>
          <li style="margin-bottom: 10.0px">
            Phase 1 study of CDX-1127, Celldex&#8217;s first therapeutic antibody
            program, in patients with solid tumors or hematologic cancers.
            CDX-1127 is a fully human monoclonal antibody targeting CD27.
          </li>
          <li style="margin-bottom: 10.0px">
            Phase 1 trial of CDX-301, an immune and stem cell growth factor,
            in healthy subjects in collaboration with a leading academic
            institution. Celldex&#8217;s first priority is to develop this molecule
            for hematopoietic stem cell transplant, where it has demonstrated
            improvement of immune cell reconstitution in preclinical <i>in vivo</i>
            models.
          </li>
        </ul>
      </li>
    </ul>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Further Financial Highlights:</b>
    </p>
    <p>
      <i>Second Quarter Results</i>
    </p>
    <p>
      The net loss of $10.2 million for the second quarter of 2011 represents
      an increase of $0.7 million when compared to the net loss for the same
      period in 2010, primarily due to decreases in revenues and increases in
      interest expense, partially offset by decreases in research and
      development (R&amp;D), amortization and general and administrative (G&amp;A)
      expenses.
    </p>
    <p>
      Revenues for the second quarter of 2011 decreased when compared to the
      second quarter of 2010 due primarily to $1.3 million in Pfizer non-cash
      deferred revenue related to rindopepimut recognized in 2010.
    </p>
    <p>
      R&amp;D expenses in the second quarter of 2011 and 2010 were $7.2 million
      and $7.3 million, respectively. Changes in R&amp;D expenses between 2011 and
      2010 primarily reflect higher costs related to personnel, the ACT III
      and ACT IV rindopepimut clinical trials (2010 costs for ACT III were
      funded by Pfizer), and laboratory supplies and services in 2011, offset
      by lower contracted research and contract manufacturing expenses as well
      as lower license/milestone payments to licensors in 2011.
    </p>
    <p>
      Royalty expense includes product royalty and sublicense royalty fees on
      the Company&#8217;s out-licensed programs. The $0.2 million increase in
      royalty expenses in 2011 primarily reflects an increase in Rotarix<sup>&#174;</sup>-related
      royalty fees. Retained interests in Rotarix<sup>&#174;</sup> net
      royalties, which were not sold to Paul Royalty Fund, are recorded as
      product royalty revenue and a corresponding amount that is payable to
      Cincinnati Children&#8217;s Hospital (CCH) is recorded as royalty expense.
    </p>
    <p>
      G&amp;A expenses decreased by $0.4 million to $2.2 million in the second
      quarter of 2011 as compared to G&amp;A expense of $2.6 million in the second
      quarter of 2010 primarily due to lower stock-based compensation, patent
      and other professional services expenses recorded during the three
      months ended June 30, 2011.
    </p>
    <p>
      <i>Six Month Results</i>
    </p>
    <p>
      The net loss of $20.3 million for the first six months of 2011
      represents an increased loss of $4.2 million when compared to the net
      loss of $16.1 million for the same period in 2010. The increased loss
      resulted from lower revenues and other income amounts, partially offset
      by lower operating expenses in 2011.
    </p>
    <p>
      Revenues for the first six months of 2011 decreased by $2.2 million when
      compared to the first six months of 2010 due primarily to $2.6 million
      in Pfizer non-cash deferred revenue related to rindopepimut recognized
      in 2010.
    </p>
    <p>
      R&amp;D expense in the first six months of 2011 was $14.0 million, an
      increase of $0.3 million compared to $13.7 million in 2010. Increases in
      costs related to personnel, the ACT III and ACT IV rindopepimut clinical
      trials (2010 costs for ACT III were funded by Pfizer), and laboratory
      supplies and services in 2011 were offset in part by decreases in
      contracted research and contract manufacturing expenses,
      facility-related costs and license/milestone payments in 2011. Royalty
      expenses for 2011 increased by $0.4 million due to increased royalty
      expense to CCH.
    </p>
    <p>
      G&amp;A expense decreased by $0.8 million to $4.6 million in 2011 as
      compared to G&amp;A expense of $5.4 million in the first six months of 2010,
      primarily due to reduced stock-based compensation, patent and other
      professional services expenses incurred in 2011.
    </p>
    <p>
      The $1.2 million decrease in amortization expense for the six months
      ended June 30, 2011 was primarily due to the amortization in 2010 of
      intangible assets acquired in connection with the CuraGen acquisition.
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      The $3.3 million decrease in investment, other income and interest
      expense, net in 2011 is primarily due to other income of $3.0 million
      recorded for the TopoTarget sublicense income payment received in 2010.
    </p>
    <p>
      As of June 30, 2011, Celldex had approximately 44.1 million shares
      outstanding.
    </p>
    <p>
      <u><i>Webcast and Conference Call</i></u>
    </p>
    <p>
      Celldex will host a conference call and live webcast at 8:30 AM ET on
      Wednesday, August 3, 2011, to provide an update on anticipated research
      and development and business objectives for the remainder of 2011. The
      conference call will be webcast live over the Internet and can be
      accessed by logging on to the &quot;News &amp; Events&quot; section of the Celldex
      Therapeutics website at <u>www.celldextherapeutics.com</u>. The call can
      also be accessed by dialing 888-713-4211 (within the United States) or
      617-213-4864 (outside the United States). The passcode for participants
      is 26193647.
    </p>
    <p>
      A replay of the call will be available approximately two hours after the
      live call concludes through August 17, 2011. To access the replay, dial
      888-286-8010 (within the United States) or 617-801-6888 (outside the
      United States). The passcode is 97860074. The webcast will also be
      archived on the Company&#8217;s website.
    </p>
    <p>
      <b>About Celldex Therapeutics, Inc.</b>
    </p>
    <p>
      Celldex Therapeutics is the first antibody-based combination
      immunotherapy company. Celldex has a pipeline of drug candidates in
      development for the treatment of cancer and other difficult-to-treat
      diseases based on its antibody focused Precision Targeted Immunotherapy
      (PTI) Platform. The PTI Platform is a complementary portfolio of
      monoclonal antibodies, antibody-targeted vaccines and immunomodulators
      used in optimal combinations to create novel disease-specific drug
      candidates. For more information, please visit <u>http://www.celldextherapeutics.com</u>.
    </p>
    <p>
      <i><b>Safe Harbor Statement Under the Private Securities Litigation
      Reform Act of 1995:</b></i> <i>This release contains &#8220;forward-looking
      statements&#8221; made pursuant to the safe harbor provisions of the Private
      Securities Litigation Reform Act of 1995, including those related to the
      Company&#8217;s strategic focus and the future development and
      commercialization (by Celldex and others) of rindopepimut (CDX-110),
      CDX-1307, CDX-011, CDX-1135 (formerly TP10), CDX-1401, CDX-1127,
      Belinostat and other products</i>. <i>Forward-looking statements reflect
      management's current knowledge, assumptions, judgment and expectations
      regarding future performance or events. Although management believes
      that the expectations reflected in such statements are reasonable, they
      give no assurance that such expectations will prove to be correct and
      you should be aware that actual results could differ materially from
      those contained in the forward-looking statements. Forward-looking
      statements are subject to a number of risks and uncertainties,
      including, but not limited to, our ability to obtain additional capital
      on acceptable terms, or at all, including the additional capital which
      will be necessary to complete the clinical trials that we plan to
      initiate in 2011; our ability to adapt APC Targeting Technology<sup>TM</sup>
      to develop new, safe and effective vaccines against oncology and
      infectious disease indications; our ability to successfully complete
      product research and further development of our programs; the
      uncertainties inherent in clinical testing; our limited experience in
      bringing programs through Phase 3 clinical trials; our ability to manage
      research and development efforts for multiple products at varying stages
      of development; the timing, cost and uncertainty of obtaining regulatory
      approvals; the failure of the market for the Company's programs to
      continue to develop; our limited cash reserves and our ability to obtain
      additional capital on acceptable terms, or at all; our ability to
      protect the Company&#8217;s intellectual property; the loss of any executive
      officers or key personnel or consultants; competition; changes in the
      regulatory landscape or the imposition of regulations that affect the
      Company&#8217;s products; and other risks detailed from time to time in the
      Company's filings with the Securities and Exchange Commission, including
      the Company's Form 10-K for the fiscal year ended&#160;December 31, 2010,
      and&#160;its&#160;Forms 10-Q and 8-K.</i>
    </p>
    <p>
      <i>All forward-looking statements are expressly qualified in their
      entirety by this cautionary notice. You are cautioned not to place undue
      reliance on any forward-looking statements, which speak only as of the
      date of this release. We have no obligation, and expressly disclaim any
      obligation, to update, revise or correct any of the forward-looking
      statements, whether as a result of new information, future events or
      otherwise.</i>
    </p>
    <div style="text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 8pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td colspan="17">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="17">
          <b>CELLDEX THERAPEUTICS, INC.</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="17">
          <b>(In thousands, except share and per share amounts)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          <b>CONSOLIDATED STATEMENTS</b>
        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="7">
          <b>Quarter</b>
        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="7">
          <b>Six Months</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          <b>OF OPERATIONS DATA</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px" colspan="7">
          <b>Ended June 30,</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px" colspan="7">
          <b>Ended June 30,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2011</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2011</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2010</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="7">
          <b>(Unaudited)</b>
        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="7">
          <b>(Unaudited)</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          <b>REVENUE</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Product Development and
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 25.0px">
          Licensing Agreements
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          11
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,399
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          25
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,746
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Contracts and Grants
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          220
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Product Royalties
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,941
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,552
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          4,443
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          3,698
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Total Revenue
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,952
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,951
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          4,468
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          6,664
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          <b>OPERATING EXPENSE</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Research and Development
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          7,169
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          7,256
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          14,021
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          13,694
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Royalty
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,941
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,732
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          4,443
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          4,059
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          General and Administrative
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,240
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,591
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          4,626
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          5,426
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Gain on Sale of Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (50
        </td>
        <td valign="bottom" style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          -
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Amortization of Acquired Intangible Assets
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          483
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          658
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          966
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,178
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Total Operating Expense
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          11,833
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          12,237
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          24,006
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          25,357
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Operating Loss
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (9,881
        </td>
        <td valign="bottom" style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (9,286
        </td>
        <td valign="bottom" style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (19,538
        </td>
        <td valign="bottom" style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (18,693
        </td>
        <td valign="bottom" style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Investment and Other Income, Net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          79
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          95
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          163
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          3,257
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Interest Expense
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (434
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (334
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (920
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (671
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          Net Loss
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (10,236
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (9,525
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (20,295
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (16,107
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Basic and Diluted Net Loss per
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 15.0px">
          Common Share
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (0.27
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (0.30
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (0.58
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          (0.51
        </td>
        <td valign="bottom" style="text-align: left; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          )
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Weighted Average Common
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 15.0px">
          Shares Outstanding
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          37,463
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          31,815
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          34,770
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          31,755
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          <b>CONDENSED CONSOLIDATED</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; border-bottom: solid black 1.0pt; padding-left: 5.0px">
          <b>BALANCE SHEETS</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px" colspan="3">
          <b>June 30,</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="text-align: center; border-bottom: solid black 1.0pt; padding-left: 0.0px" colspan="3">
          <b>December 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2011</b>
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" colspan="3">
          <b>2010</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="7">
          <b>(Unaudited)</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          <b>ASSETS</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Cash, Cash Equivalents and Marketable Securities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          71,236
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          61,098
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Other Current Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          2,053
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          1,849
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Property and Equipment, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          9,985
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          10,832
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px">
          Intangible and Other Assets, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          35,202
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          36,164
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 4.0px; padding-left: 20.0px">
          Total Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          118,476
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          109,943
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Current Liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          10,409
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          20,208
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 5.0px">
          Long-Term Liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          16,062
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          14,480
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px">
          Stockholders' Equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          92,005
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: solid black 1.0pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          75,255
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 4.0px; padding-left: 15.0px">
          Total Liabilities and Stockholders' Equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          118,476
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
        <td>

        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="text-align: right; border-bottom: double black 2.25pt; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px">
          109,943
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      CONTACT:<br>Celldex Therapeutics, Inc.<br>Anthony S. Marucci,
      781-433-0771<br>President and CEO<br>or<br>Celldex Therapeutics, Inc.<br>Avery
      W. Catlin, 781-433-0771<br>Chief Financial Officer<br><u>IR@celldextherapeutics.com</u><br>or<br><u>For
      Media:</u><br>BMC Communications<br>Brad Miles, 212-477-9007 x17<br><u>brad@bmccommunications.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
